IGF-1, the insulin-like growth factor, in everyday words
CJC-1295 and IGF-1: why IGF-1, the insulin-like growth factor, rose
This page shows you what CJC-1295 changed in blood, how long it lasted, and why that doesn’t prove better health.
An accessible, plain-language digest of what the published CJC-1295 research actually shows on the growth-hormone / IGF-1 axis - laid out as a curated board of the studies, the kinetics, and the honest data gaps.
What changed when people got CJC-1295?
Scientists make CJC-1295 as a short row of protein pieces. That row is called a peptide. CJC-1295 makes your growth gland raise the amount of growth hormone in your blood. This page covers what small studies found and what they can’t prove. Healthy adults got shots holding 30 or 60 micrograms for every kilogram they weighed [1]. One gram contains a million micrograms.
Average growth hormone rose from 2- to 10-fold, or two through ten times the earlier reading. IGF-1 is short for insulin-like growth factor, a hormone that helps with growth. It rose 1.5- to 3-fold, or between one-and-a-half and three times. After more CJC-1295 shots, IGF-1 was still high on day 28.
After about 5.8 to 8.1 days, the body had cleared half of the long CJC-1295 form [1]. The rest left more slowly over more time. An added part latches onto albumin, a plentiful protein carried in blood [2]. That link makes the drug leave your blood more slowly.
Here’s the limit I’d keep in mind for you. A few small studies from the mid-2000s looked at people and animals [1][2][3][4]. They didn’t prove that CJC-1295 helps healthy adults feel better or is safe for years. That IGF-1 blood reading can’t tell you how you’ll feel, because a rise in IGF-1 doesn’t prove your daily life or health will get better in the days ahead. The pages on the two forms, hormone results, and time in blood can’t tell you whether your health will improve or which amount would fit you.
What is CJC-1295 made from?
CJC-1295 starts with the first 29 amino acids. These are the small parts that make a protein [2]. Researchers swapped parts 2, 8, 15, and 27 [2]. Those swaps keep the chain from breaking apart so fast. Papers call that short piece the 1-29 form.
CJC-1295 isn’t a steroid or growth hormone. It makes your growth gland release a hormone your body produces. The insulin-like growth factor called IGF-1 rises next [1]. Lab workers use the drug’s weight, 3,368 daltons, to check its identity; that weight can’t show whether it helps you.
Researchers gave shots just beneath the skin because digestion tears apart protein chains like this [1][3]. The long form can join with the blood protein albumin; the short 1-29 form can’t [2]. That’s why the long one stays in blood much longer. If we were reading a result together, I’d first mark which form the study used on the form page.
How do the two CJC-1295 forms differ?
Your blood contains a protein called albumin. The long form joins that protein and remains longer [2]. The short 1-29 form lacks that link and wears off much sooner. Papers use the 1-29 label because this form copies the first through twenty-ninth protein parts of a natural hormone.
What does CJC-1295 change in your blood?
The drug makes the growth gland add growth hormone to the bloodstream. Your liver then makes more IGF-1, short for insulin-like growth factor. In healthy adults, IGF-1 stayed high while the body cleared half the long form in 5.8 to 8.1 days [1]. One shot can change your blood tests for days after you leave the clinic.
What is ipamorelin, and why pair the two drugs?
Ipamorelin is another test drug made from small protein parts. It causes hormone release by a different route than CJC-1295. In lab work, using both brought a larger growth-hormone release [5]. That result didn’t show better health in a person.
Researchers haven’t run a controlled human trial showing that the CJC-1295 and ipamorelin pair helps healthy adults. No such trial has found a safe amount. The CJC-1295 lab result poses a question for more study; it isn’t a health promise. The pairing details show you where the proof ends.
Where can you read the full papers?
The study page covers four main papers. One 2006 paper tested adults, another 2006 paper checked their brief hormone releases, a 2005 study used rats, and a third 2006 study used mice. The amounts page lists what people and animals received. It also explains how fast CJC-1295 left the blood and what happened to IGF-1, the insulin-like growth factor.
The two forms page explains why the short form wears off sooner. You can compare CJC-1295 with the shorter drug sermorelin, then read the CJC-1295 safety answers. The paper list gives each title, author, and code used to find the paper. You or a librarian can use that list to find the original CJC-1295 work.
What can personal reports tell you?
Benefits & Risks separates reports from study findings. It tells you what people noticed, but those stories can’t predict your result. It also shows what trials haven’t checked for you or your health.